NCT05968326

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2023-10-18Est. Completion: 2031-01-01

Enrollment target: 260 participants

Locations

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
USC Norris Cancer Center, Newport Beach, California, United States
University of California, San Francisco (UCSF), San Francisco, California, United States
University of California Los Angeles, Santa Monica, California, United States
St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
Smilow Cancer Center, New Haven, Connecticut, United States
Yale Cancer Center, New Haven, Connecticut, United States
Smilow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
University of Kentucky Medical Center, Lexington, Kentucky, United States
Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center, Boston, Massachusetts, United States
Boston Medical Center (BMC) - Cancer Care Center, Boston, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States

Pancreatic Ductal Adenocarcinoma

This study is open to adults with advanced pancreatic cancer. The study tests a type of immunotherapy. It is a protein t…

Los Angeles, United StatesEst. completion Mar 8, 2027

Metastatic Pancreatic Ductal AdenocarcinomaPDAC

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gl…

Tyler, United StatesEst. completion Jun 2031

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.